Tuesday, January 20, 2015

Defense Stocks Conversation with Scott Sacknoff, Manager, SPADE Defense Index (NYSE: ^DXS)



Defense Stocks Conversation with Scott Sacknoff, Manager, SPADE Defense Index (NYSE: ^DXS)

The question being asked is, “How should investors look at the terrorism events in Paris?”


Point Roberts WA, NEW YORK, NY – January 20, 2015 – ( www.investorideas.com newswire and Homelanddefensestocks.com) - Investorideas.com, a global news source covering leading sectors including defense and security, issues recent commentary from  Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS) following the recent Paris attacks and increased global terrorism events.

Scott Sacknoff manages the SPADE Defense Index (NYSE: DXS) which serves as the underlying index for PowerShares Aerospace & Defense ETF (NYSE: PPA).  http://www.spadeindex.com/

The question being asked is, “How should investors look at the terrorism events in Paris?”

Scott Sacknoff, President of Spade Defense Index:

Terrorism is once again front and center in the news.  The physical attacks in Paris in January 2015 were among a number that have taken place over the past few weeks, including a raid by Belgian authorities killing two suspected terrorists, an Ohio man who plotted to attack the U.S. Congress, satellite images showing that Boko Haram wiped out a number of villages in Nigeria, as well as their kidnapping of around 80 people in Cameroon; and of course, this doesn’t even mention any of the cyber-focused attacks, which are not addressed here. 

The human impact to attacks such as these are of course clear but the financial/investing impact is less so.  Identifying firms that benefit immediately after terrorist actions is not as easy as it sounds.  Even after 9/11 almost all stocks in the United States declined immediately, including defense and security stocks.  These rose once the situation stabilized a bit and plans to increase funding to combat the terrorists were announced.  Still one can draw conclusions. A bombing on a plane will lead to increased security measures at airports; so firms that manufacture scanners, such as American Science and Engineering (ASEI) or OSI Systems (OSIS), should benefit and see increased orders over time. Likewise if a missile were to down a plane, there would be calls for installing anti-aircraft devices on commercial planes and so one would assume a rise in stocks of companies that manufacture those devices.  But the correlation is not absolute. With a steady frequency of events, there is a history now that shows additional funding does not necessarily flow immediately following a terrorist event; one must consider the likelihood and availability of whether funds for the new contracts will come. 

As another example, following several recent police interactions that led to deaths in Missouri, New York, and elsewhere, there was a call for the police to utilize video collection systems to record events in real-time.  After statements from elected officials stating their willingness to allocate funds, one can see that there was an obvious rise in the stock price of Taser (TASR), which offers said product. Whether it can maintain these levels depends on whether municipalities deliver on their plans to buy their product.   

Where security and defense stocks do benefit, consistently, is that the increased publicity of terrorist activities leads to an underlying sense that we are never totally safe. It is in this environment that spending on defense and security are considered an important part of government funding and the sector can operate within a stable budget environment. And a stable environment is one that benefits most firms. 


Q: Investorideas.com:
Regarding Paris, are there technologies that investors should look toward that might be employed to prevent situations like what occurred?   

A: Scott Sacknoff, President of Spade Defense Index
It appears from news reports, including an excellent summary in the New York Times, that the lead instigators in Paris were known to authorities, had been arrested, and were on terrorist watch lists.  Over time, French authorities appeared to decide that after years of inaction, at least that they were aware of, it was no longer necessary to track these persons. No matter the technology employed, even those some believe cross the boundaries of personal freedoms, it is still the human element that sometimes makes the call.

Still technology is critical to helping identify potential problems, whether dealing with “lone wolf” actions of an individual, or small groups acting on their own or those associated with a terror cell or network.  And even when it fails to identify the threat in advance, as it did in Paris or the Boston Marathon, technology solutions were critical to capturing the suspects and stopping them before they were able to pursue future attacks.

Key technologies in these efforts are analytics for mining big data including automated video analysis, and surveillance and reconnaissance systems and networks. All of these should see growth in the coming years.  In the world of security, using statistical correlations and identifying patterns can be like looking for a needle in a haystack. Still money is flowing in this direction.  The inherent value is known to commercial entities (to identify consumer trends and process efficiencies) as well as to the counterterrorism sector.  Firms operating at the intersection of security, cyber, and big data include: Lockheed Martin, Booz Allen, CACI, and FireEye, to name but a few, as well as the more commercial IBM, HP, Amazon, Cloudera, and Splunk’s of the world.


Q: Investorideas.com:
Can you quantify investor reaction to these recent events?

A: Scott Sacknoff, President of Spade Defense Index
Significant inflows into the Powershares Aerospace & Defense ETF (NYSE: PPA), the fund that tracks the benchmark SPADE Defense Index, have been detected over the past year. However, considering the fund was up more than 48% in 2013 and nearly 12% in 2014, and the Paris attacks coincided with a broad global market decline, there is really no way to correlate gains in the fund with investors’ actions. 






InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Spade Defense Index Disclaimer:  The information presented here is for information purposes only and should not represent a solicitation or an offer to purchase an investment product.

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news  and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411




Tuesday, December 2, 2014

Ongoing Cyber Threats and Recent Sony Hacking Draw Attention to Cybersecurity Stocks

Ongoing Cyber Threats and Recent Sony Hacking Draw Attention to Cybersecurity Stocks

New York NY- Point Roberts WA–December 2, 2014 – Investorideas.com (www.investorideas.com), a global news source covering leading sectors including cybersecurity releases the updated cybersecurity stock directory for December, following the recent high – profile Sony hacking.

The recent hacking at Sony Pictures  by a group working under #GOP has resulted in the illegal release and distribution of  "Still Alice,'' ''Annie," ''Mr. Turner," and ''To Write Love on Her Arms".

With new cyber threats emerging daily, the sector has gained attention from investors and institutions.

It has also resulted in the recent launch of PureFunds ISE Cyber Security™ ETF (HACK).

Investorideas.com recently interviewed Christian Magoon, consultant to ISE ETF Ventures and Founder and CEO of YieldShares, to gain insight into the creation of the ETF and its future.


CyberSecurity Stocks Directory Preview
Absolute Software Corporation (TSX: ABT.TO) is the industry standard in persistent endpoint security and management for computers, laptops, tablets and smartphones. The Company, a leader in device security and management tracking for 20 years, has over 30,000 commercial customers worldwide. Absolute's solutions - Computrace®, Absolute Manage®, Absolute Service, Absolute Secure Drive, and Absolute LoJack® - provide organizations with actionable intelligence to prove compliance, securely manage BYOD, and deliver comprehensive visibility and control over all of their devices and data. Absolute is positioned on two Gartner, Inc. Magic Quadrants - the Magic Quadrant for Client Management Tools and the Magic Quadrant for Mobile Device Management Software. Absolute is one of only four vendors to be recognized on both Magic Quadrants based on providing customers with the ability to secure and manage many different types of devices using a single solution. Absolute persistence technology is embedded in the firmware of computers, netbooks, tablets and smartphones by global leaders, including Acer, ASUS, Dell, Fujitsu, HP, Lenovo, Motion, Panasonic, Samsung, and Toshiba, and the Company has reselling partnerships with these OEMs and others, including Apple.
AT&T Inc. (NYSE: T) AT&T Government Services (AGS), a business unit of AT&T Corp., delivers IT solutions spanning cyber security, networking, wireless, mission support and applications. Thousands of experienced AGS personnel, along with certified professionals throughout the AT&T family of companies, focus exclusively on supporting the federal government.
AVG Technologies N.V. (NYSE:AVG) is the online security company providing leading software and services to secure devices, data and people.  AVG has over 182 million active users, as of June 30, 2014, using AVG's products and services including Internet security, performance optimization, and personal privacy and identity protection. By choosing AVG's products, users become part of a trusted global community that engages directly with AVG to provide feedback and offer mutual support to other customers.
Barracuda Networks (NYSE:CUDA) provides cloud-connected security and storage solutions that simplify IT. These powerful, easy-to-use and affordable solutions are trusted by more than 150,000 organizations worldwide and are delivered in appliance, virtual appliance, cloud and hybrid deployments. Barracuda's customer-centric business model focuses on delivering high-value, subscription-based IT solutions that provide end-to-end network and data security.Barracuda Networks has developed a worldwide reputation as the go-to leader for providing government agencies with powerful yet easy-to-use IT solutions that simplify the most complex security, storage, application delivery, networking and data protection challenges.
BlackBerry (Research in motion) (NasdaqGS:BBRY; TSX:BB.TO) a global leader in wireless innovation, revolutionized the mobile industry with the introduction of the BlackBerry® solution in 1999. Today, BlackBerry products and services are used by millions of customers around the world to stay connected to the people and content that matter most throughout their day. Founded in 1984 and based in Waterloo, Ontario, RIM operates offices in North America, Europe, Asia Pacific and Latin America. Integral security features and an ever-expanding administrative toolset have earned BlackBerry® products the trust of some of the most secure organizations in the world. These security features have also made the BlackBerry solution a world leader in mobile security certifications
CA Technologies. (NasdaqGS:CA) provides IT management solutions that help customers manage and secure complex IT environments to support agile business services. Organizations leverage CA Technologies software and SaaS solutions to accelerate innovation, transform infrastructure and secure data and identities, from the data center to the cloud.
Cecurity.com (Paris:MLCEC.PA) is a French company and since 2001 the leader in publishing electronic vault software for the control of original digital documents. The areas of expertise of the Cecurity Group cover dematerialisation, legal archiving, data protection, traceability and certified electronic mail. Through its subsidiaries, the Cecurity Group is also a provider of services. These services are based on the use of its own technologies in SaaS (Software as a Service) mode.
Check Point Software Technologies Ltd. (NasdaqGS:CHKP) the worldwide leader in securing the Internet, provides customers with uncompromised protection against all types of threats, reduces security complexity and lowers total cost of ownership. Check Point first pioneered the industry with FireWall-1 and its patented stateful inspection technology. Today, Check Point continues to develop new innovations based on the Software Blade Architecture, providing customers with flexible and simple solutions that can be fully customized to meet the exact security needs of any organization. Check Point is the only vendor to go beyond technology and define security as a business process. Check Point 3D Security uniquely combines policy, people and enforcement for greater protection of information assets and helps organizations implement a blueprint for security that aligns with business needs. Customers include tens of thousands of organizations of all sizes, including all Fortune and Global 100 companies. Check Point's award-winning ZoneAlarm solutions protect millions of consumers from hackers, spyware and identity theft.
Cisco Systems Inc. (NASDAQGS: CSCO) is the worldwide leader in IT that helps companies seize the opportunities of tomorrow by proving that amazing things can happen when you connect the previously unconnected. Security Solutions
CommVault Systems, Inc. (NasdaqGS:CVLT) A singular vision – a belief in a better way to address current and future data management needs – guides CommVault in the development of Singular Information Management® solutions for high-performance data protection, universal availability and simplified management of data on complex storage networks. CommVault's exclusive single-platform architecture gives companies unprecedented control over data growth, costs and risk. CommVault's Simpana® software suite of products was designed to work together seamlessly from the ground up, sharing a single code and common function set, to deliver superlative Data Protection, Archive, Replication, Search and Resource Management capabilities. More companies every day join those who have discovered the unparalleled efficiency, performance, reliability, and control only CommVault can offer.
Computer Services, Inc. (CSI) (OTC: CSVI) delivers core processing, managed services, mobile and Internet solutions, payments processing, print and electronic distribution, and regulatory compliance solutions to financial institutions and corporate customers across the nation. Exceptional service, dynamic solutions and superior results are the foundation of CSI’s reputation and have resulted in the company’s inclusion in such top industry-wide rankings as the FinTech 100, Talkin’ Cloud 100 and MSPmentor Top 501 Global Managed Service Providers List. CSI Managed Security.
CSP Inc (NasdaqGM: CSPI) and its subsidiaries develop and market IT integration solutions and high-performance computer systems to meet the diverse requirements of our industrial, commercial, and defense customers worldwide. CSP, Inc's High Performance Products & Solutions segment includes the MultiComputer Division, which designs and manufactures commercial high-performance computer signal processing systems for a variety of complex real time applications in defense and commercial markets. The Company also owns Myricom, a pioneer in high performance computing interconnect technology. Founded in 1970, Modcomp, Inc. is part of CSPI's Information Technology Solutions segment, and has offices in North America and Europe. Modcomp provides solutions and services for complex IT environments including disaster recovery, mobility, managed services, security, data center management, and collaboration.
Cybergy Partners, Inc. (OTC:MKHD) team of approximately 110 employees delivers innovative technical and management services through its 3 divisions: New West Technologies, which was founded in 1996 and provides clean, smart, and reliable energy solutions and is a 5 time winner of the Inc. 500/5000 fastest growing private companies in America; Primetrix, which serves U.S. Federal Government contractor firms with contract procurement, compliance, and growth services; and Cybergy Labs, an award-winning developer of specialized cybersecurity software applications including SmartFile.
Digimarc Corp. (NasdaqGS:DMRC) is a leading innovator and provider of enabling technologies that create digital identities for all forms of media and many everyday objects. Digimarc's digital IDs are imperceptible to humans and enable computers, networks and devices like mobile phones to better "see, hear and understand" brand impressions and other objects of interest. Digimarc has built an extensive intellectual property portfolio with patents in digital watermarking, content identification and management, media and object discovery to enable ubiquitous computing and related technologies. Digimarc develops solutions, licenses its intellectual property, and provides development services to business partners across a range of industries.

See the full directory plus others: http://www.investorideas.com/membership/



About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for our free news alerts

Become an Investorideas.com Member and use our online stock directories to research stocks – including cybersecurity, biometric and mobile payment stocks http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source – www.Investorideas.com





Wednesday, November 26, 2014

Biodefense Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States

Biodefense Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States

SAN DIEGO - November 26, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus infections in the United States. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.


Aethlon disclosed that four Hemopurifiers have been shipped to the Biocontainment Unit at the Nebraska Medical Center (NMC) in Omaha as a therapeutic option to be stockpiled for Ebola patients that may be treated at the NMC. Aethlon further disclosed that it has provided onsite training to NMC clinical personnel related to the implementation of Hemopurifier® therapy within the dialysis infrastructure already located at the center.

The Nebraska Biocontainment Unit was commissioned by The United States Centers for Disease Control (CDC) in 2005. It is a joint project involving Nebraska Medicine, Nebraska Health and Human Services, and the University of Nebraska Medical Center. It was designed to provide the first line of treatment for people affected by bioterrorism or extremely infectious naturally occurring diseases such as Ebola. It's the largest facility of its kind in the U.S. The NMC has treated three Ebola patients since the current outbreak. Additional details can be found online at: www.nebraskamed.com/biocontainment-unit

Aethlon previously reported the successful administration of Hemopurifier® therapy to a Ugandan doctor who was infected with Ebola virus and treated at the Frankfurt University Hospital in Germany. At the time Hemopurifier® therapy was administered, the doctor was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported.

Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment. The doctor has since made a full recovery and has returned home to his family in Uganda.

In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. Aethlon disclosed that it provided Hemopurifiers to the NMC on a humanitarian basis and therefore will not generate revenues as a result of its initial shipment.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against bioterror and pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).


About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device that selectively targets the broad-spectrum elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
Leah-Michelle Nebbia (for interview requests) 
Golin
 
202-585-2651
 
lnebbia@golin.com

James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and more...






Tuesday, November 25, 2014

Ebola Patient Who Received Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital

Biodefense Breaking News: Ebola Patient Who Received Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital

SAN DIEGO - November 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that an Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients.



The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At the time Hemopurifier® therapy was administered to the Ugandan physician, he was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment.

In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against bioterror and pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).


About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device that selectively targets the broad-spectrum elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
Leah-Michelle Nebbia (for interview requests) 
Golin
 
202-585-2651
 
lnebbia@golin.com

James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and more...





Friday, November 14, 2014

Biodefense News: Aethlon Medical's (OTCBB: AEMD) Hemopurifier® Used in Successful Treatment of Patient with Advanced Ebola Infection

Biodefense Breaking News: Aethlon Medical's (OTCBB: AEMD) Hemopurifier® Used in Successful Treatment of Patient with Advanced Ebola Infection

242 Million Copies of Ebola Virus Removed from Patient during Treatment, Physician Reports at American Society of Nephrology Annual Meeting

SAN DIEGO and PHILADELPHIA - November 14, 2014 (Investorideas.com newswire) The Aethlon Hemopurifier® was used in the successful treatment of a critically-ill Ebola-infected patient in Frankfurt, Germany, according to data presented today at the American Society of Nephrology (ASN) Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital. Geiger reported that 242 million Ebola viruses were captured within the Aethlon Hemopurifier® during treatment, a number verified by a post-treatment elution protocol. The patient is no longer infected with Ebola virus and is expected to make a full recovery.


Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to treat infectious disease, created the Hemopurifier®, a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.

The Frankfurt University Hospital patient, a Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients, was not administered Hemopurifier® therapy until 12 days after being diagnosed.

At the time of Hemopurifier® administration, Dr. Geiger reported that the Ebola patient was unconscious and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications.

The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported.

Since the administration of Hemopurifier® therapy, Frankfurt University Hospital officials have reported that Ebola virus is no longer detectable in the patient's blood and full recovery is expected.

"The rate of viral load reduction and magnitude of Ebola virus captured within the Hemopurifier® is quite remarkable when considering the lethality of Ebola infection and the compromised health of the patient," stated James A. Joyce, Chairman and CEO of Aethlon Medical. "We're thrilled for the patient and applaud the tireless effort of physicians in Frankfurt who helped to save the patient's life. We will continue to advance Hemopurifier® therapy as a lead candidate to address antiviral drug resistance and the sole broad-spectrum strategy to address Ebola other viruses where drugs and vaccines have not proven to be effective."

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).


About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device that selectively targets the broad-spectrum elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com and connect with the Company on Twitter, LinkedIn,  Facebook and Google+.

Contacts:
Leah-Michelle Nebbia (for interview requests) 
Golin
 
202-585-2651
 
lnebbia@golin.com

James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and more...